What diseases does Nintedanib/Vigat treat and which patients are suitable for it?

Nintedanib is a multi-target tyrosine kinase inhibitor mainly used to treat idiopathic pulmonary fibrosis (IPF), progressive phenotypic chronic fibrosing interstitial lung diseases (ILDs) and systemic sclerosis-related interstitial lung diseases (SSc-ILD). The common feature of these diseases is fibrosis of lung tissue, leading to a gradual decline in lung function, which may be life-threatening in severe cases. The mechanism of action of nintedanib is to slow down the progression of the disease by inhibiting multiple kinases involved in the fibrosis process.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which the patient's lung tissue is gradually replaced by fibrosis, leading to loss of lung function. Nintedanib can effectively slow down the process of pulmonary fibrosis by inhibiting multiple targets such as VEGFR, FGFR, and PDGFR. The use of nintedanib can slow down the decline of lung function in IPF patients, help patients improve their quality of life, and delay the progression of the disease.

In addition, nintedanib is also indicated for the treatment of other types of interstitial lung diseases, particularly those with a progressive phenotype, chronic fibrosing interstitial lung diseases (ILDs). A common feature of these diseases is the progressive fibrosis of lung tissue, ultimately leading to a significant loss of lung function. Nintedanib helps patients delay the decline of lung function and improve their respiratory status and quality of life by blocking fibrosis-related signaling pathways.

In addition, nintedanib also has a therapeutic effect on patients with systemic sclerosis-related interstitial lung disease (SSc-ILD). SSc-ILD is a lung disease caused by systemic sclerosis and is characterized by fibrosis of the lung interstitium. Nintedanib can effectively slow down the decline of lung function in such patients, prolong the patient's survival, and reduce the aggravation of pulmonary symptoms.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib